The chemical compounds called cannabinoids, found in cannabis and hemp, are also produced naturally in the body from omega-3 fatty acids. A new study in animal tissue reveals the cascade of chemical reactions that convert omega-3 fatty acids into cannabinoids that have anti-inflammatory benefits. The findings are published in theRead
A recent New York Times article, CBD is Everywhere, But Scientists Still Don’t Know Much About It, paints a picture of snake-oil sales, hyped-up claims and minuscule science. Is that true or a journalistic stretch? The article prompted Today’s Practitioner to dig up two well-researched studies from Cannabis and CannabinoidRead
In this study, published in PLOS ONE, researchers explored the role of cannabidiol for intestinal inflammation. This research looked enteric glial cells (EGC), which plays a fundamental role in the maintenance of gut homeostasis. They assure the correct trophism of vicinal neurons in the myenteric plexus and actively participate inRead
Approximately 25 percent of drug-resistant epilepsy patients taking cannabidiol (CBD) developed a tolerance to the treatment, researchers said at the American Epilepsy Society annual meeting taking place Nov.30 – Dec. 4, 2018. The findings suggest that that the effectiveness of the CBD drug might wane in the long term forRead
Emerging research shows that cannabidiol holds unique properties as an antioxidant. In the scientific summary, we profile two studies that review the potential of non-psychotropic cannabidiol as an antioxidant. This research has future clinical implications for cerebral ischemia, rheumatoid arthritis, types I and II diabetes, atherosclerosis, Alzheimer’s disease, hypertension, theRead
In this video, Dr. DeSilva shares some case studies and how he is prescribing CBD for common conditions for his patients. In this video series he discusses the following: Case studies of patient response to CBD for sleep and auto-immunity, Researching the right brand of CBD, What to look forRead
While cannabidiol (CBD) is fast becoming a common compound for pain and anxiety relief, the exact pathways and dosage have remained elusive. A recent study, published in the journal PAIN, identified new pathways, beyond the endocannabinoid system, which explain its analgesic and anti-anxiety benefits. They are surprisingly different than whatRead
BALA CYNWYD, Pa., Oct. 16, 2018 — Dr. Sanjay Gupta, President of the American Pain Association (APA)* and a pain management specialist based in Bala Cynwyd, Penn., is leading the push for insurance companies to cover cannabidiol (CBD) products for the treatment of pain and Opioid Use Disorder. Simply put,Read
Weekly round-up, access to thought leaders, and articles to help you improve health outcomes and the success of your practice.
